Expression And Immune Effect Study Of Therapeutic Recombinant Protein Vaccine VP22â–³-mE6â–³/mE7

Cervical cancer is one of the most frequent carcinoma. According to statistics, there were 460000 new cases occoured per year and 250000 died in cervical cancer in the world. In China, there were over 130000 new sufferers per year and 50000 died due to the cancer. With the development of the researching, scientists and doctors have attached importance to the correlation between cervical cancer and HPV infection. More and more researchers make great effort to study the pathogeny of cervical cancer to enhance the treatment and defence of cervical cancer.HPV is a dds-DNA virus which consists 7800 to 7900 base pairs. There are three functional regions containing in the HPV genome. The HPV ORFs are build with six early transcription units (EI1, E2, E3, E4, E5, E6, E7) and two later transcription units (L1, L2). The E6 and E7 are reputed as cancer genes, which would bind to the P53 and PRB (retinoblastoma protein) to inhibit the activity of the cancer suppressors. There are more than 100 sub-types of HPV so far. 54 types of them could infect the tractus genitalis. High risk types HPV-16 and HPV-18 positive can be detected in some anal canal and vagina cancers.HPV-16 therapeutic vaccines, which is a simple safety and efficient approach in cervical cancer therapy, was reported wildly. Soluble vaccine always has a weaker immunogenicity, and the adjuvant was forbidden to use in human, which limited the usage of these vaccines. So the development of new build-in adjuvant vaccine has become a hot point currently.VP22 is a inter cellular transport protein of HSV-1 encoded with UL49 gene which can carry the target protein and transport to the adjacent cells. Previous study recombined the VP22 with E7 fragment of HPV to a RNA vector, the immunized mouse showed a enhanced CDS+T activity and anti E7 tumor activity. Further studies demonstrated that the 34aa in C terminal of VP22 are entail for the VP22 transportation. Because this peptide can take the client protein into other cells in form of unfold to enhance the interaction of cell and protein.Here, we have cloned the protein transduction domain of VP22 protein of HSV-1 and recombined with HPV type 16 mE6A/mE7 fragment. Then recombinant protein was served as the build-in adjuvant vaccine to evaluate the bio-effect in vivo or in vitro. Our result showed that the recombinant VP22â–³-mE6â–³/mE7 vaccine has raised not only high titer of specific IgG against HPV-16 but also has a high activity in E6/E7 tumor suppression, what could provide a brand new concept in developing the adjuvant-free vaccine.